All News
RheumNow Podcast – Pounds of Prevention (3.5.2021)
Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.
Read Article
#RA associated interstifial lung dz has incidence of 1-5 per 1,000 PYs and prevalence as high as 67%; risk factors; age, male sex, Dz duration, CCP Abs; w/ age as best predictor of mortality. There is no clear drug interventions that helps RA-ILD https://t.co/zJvWqt0w6L
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is a powerful, interactive meeting delivered by researchers, educators, & clinicians.
Sign up to attend virtually or in-person today.
https://t.co/SvLpwNYh9c
Links:
Dr. John Cush RheumNow ( View Tweet)
Why it's safe to come to RheumNow Live. Lessons learned from restaurants and flying.
https://t.co/R0eYO2GiPd https://t.co/E9vPjzUTgb
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease
https://t.co/6A4muejeH9 https://t.co/xQbIoEEscv
Links:
Dr. John Cush RheumNow ( View Tweet)
Download available--Difficult RA Defined
https://t.co/6WGMEiwiUk
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow podcast now available! Listen on SoundCloud and Apple/Android podcasts.
https://t.co/P6kaqZP0PJ https://t.co/BPQ5Ey7d0r
Links:
Dr. John Cush RheumNow ( View Tweet)
"... think what others won’t think;
go where others won’t go;
do what others won’t do;
and be what others want to be."
- Phil knight
Dr. John Cush RheumNow ( View Tweet)
News Feature: Baricitinib Therapy in Covid-19 Pneumonia
https://t.co/b3tsLcoXay https://t.co/tjqkk1RLFZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Download available--Arthritis Myths
https://t.co/2Kxpou4Fbz
Links:
Dr. John Cush RheumNow ( View Tweet)
We have a robust agenda planned for RheumNow Live. Have you registered yet?
https://t.co/3zMtzt4t2H https://t.co/iLNj8XEu4X
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Remission Time
What to do when not quite in remission
https://t.co/BjALXBPVYm https://t.co/HftUANlU1b
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow LIVE VOTE Survey (RHEUMS only):
What Kind of Rheumatologist are You?
General Rheum?
Selective Rheum?
Specialized Rheum?
please vote in our quick 4Q survey https://t.co/2c5fIgcJ5X https://t.co/LgK8yiXEWC
Links:
Dr. John Cush RheumNow ( View Tweet)
Influenza Numbers are way down this year due to COVID mitigation methods, school/office closings, reduced travel/mobility. As of Jan 31st only 155 hospitalized with the flu (98% less than 2019-2020 flu season - 8,633 people were hospitalized with the flu) https://t.co/6c2YQKbt57?
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: Weight Loss to Avert Risk of Gout
https://t.co/wzf69PvSJc https://t.co/Dph4OAC2Ar
Links:
Dr. John Cush RheumNow ( View Tweet)
2021 Rheumatollgy drugs lead television advertising spending: #1 Humira ($65.8 million); #6 Xeljanz ($33.9 mill); #7 Skyrizi ($40 mill); #8 Enbrel ($25.8mill); #9 Rinvo ($12+ mill) https://t.co/Pan9Vr5kLt
Links:
Dr. John Cush RheumNow ( View Tweet)
Today the FDA approved tocilizumab (Actemra) for use in Systemic Sclerosis-Associated Interstitial Lung Disease for "Slowing the rate of decline in pulmonary function in adult patients with SSc-ILD" Rec dose is 162 mg SC q week (IV dose not approved) https://t.co/HXTRPiYEfZ
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - I'm Ready to Fly
It's ok to Fly, go to a Resturant and come to https://t.co/9U4LaPKfJs
https://t.co/R0eYO2GiPd https://t.co/Ot9RFlmsVT
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is a powerful, interactive meeting delivered by researchers, educators, & clinicians.
Sign up to attend virtually today.
https://t.co/9IGCDMnlrb
Links:
Dr. John Cush RheumNow ( View Tweet)
Comparison of MSU crystal ID, DECT scanning and US to Dx gout - study of 147 pts. Compared to the gold standard (MSU ID), Feet/ankles (87% sensitivity; 100% specificity) or knees DECT (91% & 87%) alone had best Dx accuracy. US was inferior to DECT. https://t.co/h8ctkfeadZ
Links:
Dr. John Cush RheumNow ( View Tweet)
